Although survival has improved in recent years, the prognosis of patients with advanced pancreatic ductal adenocarcinoma (PDAC) remains poor. Despite substantial differences in anatomy, physiology, genetics, and metabolism, the overwhelming majority of preclinical testing relies on transgenic mice. Hence, while mice have allowed for tremendous advances in cancer biology, they have been a poor predictor of drug performance/toxicity in the clinic. Given the greater similarity of sus scrofa pigs to humans, we engineered transgenic sus scrofa expressing a LSL-KRAS G12D -TP53 R167H cassette. By applying Adeno-Cre to pancreatic duct cells in vitro, cells self-immortalized and established tumors in immunocompromised mice. When Adeno-Cre was administered to the main pancreatic duct in vivo, pigs developed extensive PDAC at the injection site hallmarked by excessive proliferation and desmoplastic stroma. This serves as the first large animal model of pancreatic carcinogenesis, and may allow for insight into new avenues of translational research not before possible in rodents.
INTRODUCTION
Genetically modified mouse models have revolutionized cancer research, allowing for faithful and reproducible histotypes closely representing those observed in human patients. This is particularly true in recent years, largely attributed to the availability of mixand-match systems such as Cre/lox and tTA/TRE 1 . These respective technologies continue to provide tissue specific recombination and gene inducibility, while allowing for more clinically relevant models of non-syndromic cancers. By employing such model systems, mice have offered invaluable and unprecedented insight into the etiology of diseases that generally present in late stages, such as pancreatic ductal adenocarcinoma (PDAC) 2 . However, while mice have inarguably allowed for tremendous advances in cancer, they have considerable limitations as a disease model due to vastly different physiology 3 , and the conceptual leap from mouse to human has been a culprit in the failure of many promising preclinical therapies.
The most obvious of these limitations is the mouse anatomy. The average human is roughly 2,500-3,000 times the size of an average mouse, severely limiting the use of mice for studies focused on surgical or radiologic interventions. Importantly, the domestic pig (sus scrofa) is now emerging as a viable model for cancer and many other human diseases. While the mouse (Mus musculus) genome is approximately 14% smaller than that of humans (2.5Gb compared to 2.9Gb) 4 , the sus scrofa genome is more similar at 2.7Gb 5, 6 .
Furthermore, the linkage conservation between humans and pigs is considerably more extensive than that between humans and mice 7 . As a result, pigs are more closely related to humans with respect to anatomy, physiology, and immunology 8 , and have the potential to more accurately represent a variety of human diseases, particularly those affecting the pancreas.
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The porcine pancreas is far more human-like than that of rodents, with comparable anatomical orientation and localization 9 . For instance, pig pancreata generally exhibit three distinct lobes, with the duodenal lobe corresponding to the head of the human pancreas, the connecting lobe being analogous to the uncinate process, and the splenic lobe corresponding to the tail/body of the pancreas 9 . In light of these many similarities, modeling pancreatic cancer in pigs would provide the opportunity to conduct surgical and radiologic studies never before possible, and may offer additional insight into disease pathogenesis due to the size and composition of the gland.
Currently, the most widely used mouse m odel of pancreatic cancer consists of concurrent KRAS G12D and TP53 172H mutations targeted to the exocrine pancreas under the Pdx-1 promoter 10 . This model (KPC) has been used extensively and is considered a gold standard within the field. We sought to generate a similar histoype in sus scrofa pigs to provide a more physiologically and anatomically relevant model. We first generated pigs harboring analogous KRAS G12D and TP53 R167H mutations, which are observed in approximately 95% and 50% of human PDAC patients respectively 11, 12 . After demonstrating the ability of these transgenes to induce adenocarcinomatous transformation of pig duct cells ex vivo, we administered an Adenoviral Cre Recombinase (Adeno-Cre) to the pig pancreas in vivo. Following refinement of the delivery system, these mutations successfully induced pancreatic neoplasms and cancer in the pig, providing the first documented large animal model of pancreatic carcinoma.
MATERIALS AND METHODS

Cloning and sequencing of porcine KRAS and TP53 genes in TOPO shuttle vector
Porcine bone marrow cells were isolated and frozen at -80°C. Total RNA was extracted from these cells with RNeasy mini kit (QIAGEN, Hilden, Germany) and reverse transcribed into cDNA with the QuantiTect Reverse Transcription Kit (QIAGEN). Ensembl genome browser was used to design the PCR primer sequences for amplification of porcinespecific KRAS (ENSSSCG00000000561) and TP53 genes (ENSSSCT00000019534 
Site-directed mutagenesis of KRAS and TP53 cDNA
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) was used to introduce changes to the nucleotide sequence corresponding to the G12D mutation into the cloned porcine KRAS cDNA and the R167H mutation into the cloned porcine TP53 cDNA.
The primers used to generate the G12D mutation in KRAS were 5'-TGGTAGTTGGAGCTGATGGCGTAGGCAAGAG-3' and 5'-CTCTTGCCTACGCCATCAGCTCCAACTACCA-3'. The primers used to generate the R167H mutation in TP53 were 5'-GAGGTGGTGAGGCACTGTCCCCACCAT-3' and 5'-ATGGTGGGGACAGTGCCTCACCACCTC-3'. Mutations were confirmed by sequencing.
Cloning of KRAS G12D and TP53 R167H cDNAs into the pIRES vector
The aforementioned KRASG12D cDNA was PCR amplified with primers 5'- 
Cloning CAG promoter into a loxP-STOP(polyA)-loxP containing vector
The pkw15 plasmid containing the CAG promoter and the pkw13 plasmid containing LoxP-STOP-(polyA)-loxP were used for the vector construction. A CAG promoter was isolated by SpeI/MfeI digestion and cloned into the pkw13 plasmid at SpeI/EcoRI cloning sites.
Construction of the inducible KRAS G12D and TP53 R167H oncopig expression vector
The KRAS G12D -TP53 R167H -pIRES vector was digested with PvuI and NheI, and the resulting KRAS G12D -IRES-TP53 R167H -polyA fragments were gel purified and cloned into CAG-LSL-pkw13 vectors at PacI/NheI sites. cDNA sequences of KRAS G12D and TP53 R167H in the final vector were confirmed correct in the resultant vector by sequencing.
Generation of fetal fibroblast strains
Male fetal fibroblasts cells (FFCs) from Minnesota miniature pigs (NSRRC:0005) were collected as described 13 
Production of transgenic cells
Early passage number FFCs (P1-2) were cultured in cell culture medium (DMEM supplemented with 15% (v/v) FBS, 2.5 ng/ml basic fibroblast growth factor and 10μg/ml gentamicin) overnight and grown to 75-85% confluency. Media was replaced 4 hours prior to transfection. FFCs were washed for 1-2 min with phosphate buffered saline (PBS; Invitrogen) and harvested with 0.05% trypsin-EDTA (Invitrogen; 1 ml per 75cm 2 flask). Cells were resuspended in cell culture medium, pelleted at 600 × g for 10 min, resuspended in 10 ml
Opti-MEM (Invitrogen), and then quantified using a hemocytometer and re-pelleted. to verify the presence of both transgenes by PCR. These cells then were stored in liquid nitrogen until used as donor cells for SCNT.
Oocyte maturation, SCNT, and embryo reconstruction
Fibroblast cells identified to have integration of the transgenes (KRAS and TP53) were used as donor cells for SCNT into enucleated oocytes followed by electrical fusion and activation as previously described 15 
Embryo transfer and piglet production
More than 100 SCNT zygotes were surgically transferred to the oviducts of surrogates on the day of, or one day after, the onset of estrus. The pregnant surrogates were monitored via ultrasound throughout pregnancy. Piglets were delivered via cesarean section from surrogates by day 114-116 of gestation. Piglets are processed immediately and tissue samples were collected for establishment of cell lines and PCR genotyping. Piglets were then hand-raised until weaning (3-4 weeks of age).
Pigs and In Vivo Imaging
All animal procedures were approved by the University of Illinois Institutional Animal Care and Use Committee. All pigs used were of the LSL-KRAS G12D -TP53 R167H transgenic line as described previously 16 . LSL-KRAS G12D -TP53 R167H pigs were dosed with 4x10 9 PFU of Ad5CMVCre-eGFP (Adeno-Cre), either directly into the body of the pancreas or into the pancreatic duct pushed toward the pancreas. For all cases the pancreas was accessed surgically through a ventral midline incision. Anesthesia was induced with TKX (Telazol, Ketamine, Xylazine), intubated and maintained in a surgical plane of anesthesia with Isoflurane.
Following recovery, all animals were monitored for general health, weight and periodic blood chemistry evaluation. For euthanasia, each animal was sedated and euthanized with sodium pentobarbital overdose (Fatal plus 10 cc/100 lbs.). All animals underwent gross and histopathologic evaluation. Tissues were then collected and subject to gross and histopathologic analysis.
For in vivo imaging, animals were sedated as described previously and 120ml of the contrast agent Iohexal (Omnipaque) was delivered intravenously, allowing for visualization of potential pathologies by contrast computed tomography (CT). Scans were limited to the cranial abdomen.
Cell Culture
The pancreas from a two-month old female pig was collected and immediately cut into Harbor, ME, USA). Tumor growth data was monitored for up to 100 days. SQ tumors were routinely measured and overall health was assessed by weight and visual inspection. Mice were sacrificed by cervical dislocation, and tissues collected and subject to histopathology.
All animal procedures were approved by the University of Illinois Institutional Animal Care and Use Committee.
RT-PCR
RNA was extracted using Trizol (Fischer-Scientific, Waltham, MA). Quantity/quality was evaluated by spectrophotometer (Nanogen Inc, San Diego, CA) and integrity confirmed via gel electrophoresis. cDNA was then synthesized using the High-Capacity cDNA Reverse 
Western blot and immunoprecipitation/RBD Assay
Cell or tissue lysates were lysed in 4% SDS buffer followed by needle homogenization. 
Study approval
All experiments involving the use of mice were performed following protocols approved by the Institutional Animal Care and Use Committee at the University of Illinois. Patient slides and information was obtained in a de-identified fashion from the Northwestern University Pathcore, following local IRB approval. All patients offered informed consent for study participation. All methods were performed in accordance with the relevant guidelines and regulations
RESULTS
KRAS and TP53 mutations induce metastatic behavior in porcine pancreatic duct cells
To assess the viability of loxp-STOP-loxp (LSL)-KRAS G12D -TP53 R167H pigs as a potential model of PDAC, we first compared the microscopic anatomy of the human, murine, and porcine pancreas. Despite the described structural differences, we found that the gland histology was remarkably similar among the three species ( Figure S1 ). In light of these similarities, we next euthanized a 2-month-old female LSL-KRAS G12D -TP53 R167H pig and removed the pancreas gland. We then extracted and digested the main pancreatic duct to isolate duct cells, and infected them with 1x10 6 Figure 1G ). SQ tumors were routinely measured and overall health was assessed by weight ( Figure S3B ). Like human PDAC, these tumors had a dense, cellular stroma, with cancer cells staining for E-cadherin, indicating an epithelial origin. These epithelial cells were distinct from the fibrous component, which was evaluated by Masson's Trichrome staining.
Furthermore, like the PORC1 cells in vitro, xenograft tumors were highly positive for CK19, affirming a ductal lineage and expressed mutant RAS G12D . Also consistent human PDAC tumors, the stroma had strong expression of αSMA, a marker of pancreatic stellate cells ( Figure 1G and Figure S3A ).
Restriction of Adeno-Cre to the Main Pancreatic Duct Leads to a Predominantly Pancreatic Ductal Adenocarcinoma Histotype
Given the sufficiency of KRAS G12D and TP53 R167H mutations to transform pancreatic duct cells in vitro, we initiated autochthonous porcine pancreatic tumor formation in vivo. Our first attempts of intraparenchymal delivery of Adeno-Cre resulted in a mixed histotype of leiomyosarcoma and duct-derived neoplasms akin to those seen in human patients (N=3, Figure S4 and S5, and Supplementary Results). Given the presence of clinically relevant pancreatic neoplasms, we next attempted to recreate the described duct-derived pancreas histotype pancreas histotype while avoiding the leiomyosarcoma phenotype observed in our initial experiments. Therefore, we repeated the above experiment focusing on transformation of ductal epithelial cells rather than mesenchyme by surgically injecting 4x10 9 units of Adeno-Cre directly into the main pancreatic duct.
One year following injection, there were no overt signs of illness or pancreatic insufficiency as observed in the previous cohort. Similarly, contrast-enhanced computed tomography (CT) showed no evidence of gross tumor formation at the injection site or near the pancreas. Additionally, the hepatobilliary tract, spleen, liver, and regional lymph nodes appeared normal with no sign of lesions. The stomach was moderately filled with gas and fluid with a mild amount of hyper-attenuating material in the dependent region of the fundus, though there was no clear sign of overt abnormality ( Figure S6A ). Furthermore, upon euthanasia, the pancreas displayed no overt signs of sarcoma and had three distinct lobes.
However, on dissection, the main pancreatic duct was large and firm with several large, nodular tumors with a pronounced fibrous component at the site of cannulation ( Figure S6B ).
Tumors were then fixed and sectioned, and compared directly to human PDAC samples. Upon histological evaluation of several geographically separate areas, porcine tumors consistently displayed morphological features consistent with human PDAC (Figure   2A,B) . In addition to having no evidence of sarcoma or smooth muscle abnormality, there were several areas consisting of lumenal masses with considerable cellular atypia and invasion through the basement membrane ( Figure 2B ). Like human PDAC, these lesions were accompanied by a dense and desmoplastic tumor stroma rich with leukocytes ( Figure   2A,B) .
Consistent with a PDAC phenotype, porcine tumor sections were positive for both Ecadherin and CK19 ( Figure 2C ). Though the predominant histotype was derived from exocrine pancreas, there were distinct and geographically separate areas that appeared to have a phenotype more similar to pancreatic neuroendocrine tumors (PNET). We therefore compared these areas directly to human PNET sections, and found that they shared several histological features, including a less pronounced desmoplastic tumor stroma ( Figure S7A,B) and stained positive for the neuroendocrine marker Synaptophysin ( Figure S7C ).
LSL-KRAS G12D -TP53 R167H -Induced PDAC Displays Excessive Proliferation
To assess changes in KRAS activity, we first performed a RAS activation assay using control and tumor tissues. As expected, in PDAC tissues KRAS protein had increased GTP binding ratio compared to control tissues, and exhibited expression of KRAS G12D and P53 R172H proteins. These were accompanied by enhanced ERK activation as determined by western blotting (Figure S8 ) and confirmed by immunohistochemistry, localizing pERK to areas suspect for PDAC ( Figure 3A and S9A) . These areas also stained strongly for PCNA, a surrogate marker of cell proliferation ( Figure 3B and S9B) , whereas adjacent normal tissue had little to no PCNA staining (data not shown). To affirm that these proliferating regions were indeed those previously identified as PDAC, we dual-stained tissues for both the ductal marker CK19 and PCNA. Regions proliferating most strongly were also CK19 positive, indicative of PDAC ( Figure 3C) . Similarly, areas suspect for PNET also displayed robust ERK activation as well as PCNA staining, further suggesting the presence of endocrine-derived neoplasms ( Figure S7D ).
Porcine PDAC Develops a Desmoplastic Stroma Analogous to Human Patients
As the pancreatic cancer stroma is not only a near uniform histological feature but also a key component of disease progression and chemo-resistance 17, 18 , we analyzed the tumor microenvironment of both human and porcine PDAC sections. As expected, all human PDAC samples examined had a dense, desmoplastic tumor stroma that stained positive with Masson's Trichrome ( Figure 4A ). Porcine tumors were similarly desmoplastic with increased Collagen IA expression ( Figure S8 ) and also stained positive with Masson's Trichrome ( Figure 4B) . Similarly, expression of the mesenchymal marker Vimentin was increased ( Figure S8 ) and localized exclusively to the tumor stroma ( Figure 4C ). As pancreatic stellate cells are considered the critical mediator of tumor-associated fibrosis 19 , we next assessed tumor sections for expression of αSMA, which was also localized to the stroma and was associated with areas of CK19-positive PDAC (Figure 4D ).
DISCUSSION
The poor survival associated with pancreatic cancer stems largely from the fact that most patients initially present with highly advanced disease. As most of these patients are not candidates for surgical intervention and there is no effective pharmacological therapy, there is Importantly, the mouse pancr eas has significant micro and macroscopic differences to that of humans. The human pancreas is a firm organ that is segmented into three borderless, yet distinct parts: the head, body, and tail 21 . In contrast, the mouse pancreas is soft and diffuse with three poorly defined lobes 22 . There are also pronounced differences of the ductal tree between the two species. In humans, the pancreatic acini are the predominant exocrine cell type and are organized into lobules that secrete to a small, intercalated duct.
These intercalated ducts drain to a larger, interlobular duct that join to form the large, main pancreatic duct which empties to the duodenum adjacent to the common bile duct 21 . In mice, however, a large interlobular duct drains the three respective lobes. Ducts from the splenic and gastric lobes then merge with the common bile duct far more proximal to the duodenum than in humans 21 .
In addition to these structural variances, there are several genetic factors that account for further differences in mouse and human carcinogenesis. Despite sharing a similar number of protein coding genes 23 , the mouse genome is substantially different from that of humans.
Though much is shared, there is significant variance in transcriptional regulation and chromatin organization between the two species 24 . This is particularly true of genes involved in the inflammatory response 25 , indicating that mice may have limited utility in inflammationassociated diseases such as pancreatic cancer 26 . Another notable disparity between mouse and human genetics is the failure of mutations in Cystic Fibrosis Transmembrane Regulator (CFTR) gene to induce significant pancreatic disease as it does in humans 27 . These issues were resolved by modeling the disease in pigs, which lead to a more faithful recapitulation of the disease pathology and destruction of the exocrine pancreas 28, 29 . We therefore attempted to recreate the success of the KPC model in the more genetically and anatomically similar sus scrofa domestic pig, in order to provide a more clinically relevant model of PDAC.
Initial attempts at intrapancreatic delivery of Adeno-Cre resulted in a mixed histotype.
While the pigs developed PanIN lesions within 16 days, we also observed lethal smooth muscle derived leiomyosarcoma, likely due to the malignant transformation of vascular smooth muscle infected with Adeno-Cre. These two cancer types generally do not present simultaneously. Therefore, it was necessary to refine our approach in order to generate a clinically relevant PDAC histotype. By restricting the delivery of our Cre using an intraductal injection, we were able to induce locally invasive PDAC without the presence of an underlying sarcoma. Interestingly, this approach also resulted in a somewhat mixed histotype, this time consisting of PDAC as well as rare and geographically isolated regions of PNET.
Mixed tumors and mixed adenoneuroendocine carcinomas (MANEC) of the gastrointestinal tract and pancreas have been well described by our group as well as many others 30 . They are commonly aggressive tumors most frequently occurring in the head of the gland and management is often a combination of surgery and platinum-based chemotherapy.
At the present time, this may be the most appropriate category for tumors induced by LSL-KRAS G12D -TP53 R167H pigs, though PDAC appeared to predominate, particularly in sections closest to the main pancreatic duct. Therefore, future work will employ improved exocrine targeting to exclude the neuroendocrine compartment.
Based on the size and anatomy of the pig, this model may allow for insight into surgical and interventional radiology techniques never before possible in rodents. Pigs and humans also have largely analogous Cytochrome P450 enzymes, allowing for better preclinical evaluation of drug metabolism and therapy 31 . Additionally, given the profound similarity between human and pig immune systems, these LSL-KRAS G12D -TP53 R167H pigs may provide an improved platform for preclinical immunotherapy. Given these advantages, several porcine models of cancer are emerging. These include a mutant APC porcine model of familial adenomatous polyposis (FAP), a heterozygous TP53 knockout model of spontaneous osteosarcomas, and a chemically induced hepatocellular carcinoma (HCC) model 32 . Similarly, our inducible LSL-KRAS G12D -TP53 R167H model has successfully generated soft tissue sarcomas and HCC 16, 32, 33 .
By demonstrating sufficiency of the LSL-KRAS G12D -TP53 R167H pig to model a humanlike pancreatic carcinoma both in vitro and in vivo (Summarized in Figure 5 ), we substantiate the pig as a more physiologically relevant platform in which to model the two predominant pancreatic cancer histotypes, allowing for novel research approaches and bridging the gap from bench to bedside. 
